Scientific journals discriminate against industry scientists, unless, that is, they happen to work for the environmental or organic industries. Those scientists don't have to follow the same rules governing the disclosure of conflicts of interest that everybody else does.
It was discovered that Ali Watkins, the newspaper's national security reporter, slept with a source who was an aide to the Senate Intelligence Committee. That source has now been arrested as part of an investigation into leaks of classified information. A breakdown in journalistic ethics, to say the least.
Dr. Oz is a fraud who ought to be fired from Columbia University and have his medical license revoked. Instead, he's headed to the White House.
No, I'm not speaking of Jonathan Goldsmith, the guy who just pretended to be The Most Interesting Man in the World. I'm speaking of the real deal, my grandfather, Dimitri Berezow -- a man who survived Stalin and Hitler, cheated death on multiple occasions, and went on to live the American dream. His was an impossibly unique story – one that seems too extraordinary to be true (and yet is) – capped with a cautionary tale about modern healthcare.
Scientists cannot publish the same figure twice. Those are the rules. One group, however, tried to pull a fast one and had the same figure in eight papers. Eight! How did journal editors find out? Easy ... they emailed each other. Now, the papers are getting their due by being retracted.
When "journalism" goes too far in tragedy.
The California Institute of Regenerative Medicine, a state-run agency that funds stem cell research, is considering funding research on human embryos using a gene-editing technology known as CRISPR-Cas9. This could potentially allow for cures to be discovered for devastating inherited diseases.
A Phase I clinical trial in France resulted in one death and hospitalization of five other study participants, three of which have irreversible brain damage. Prosecutors there are beginning a manslaughter investigation which will threaten the stability of any future drug trial.